WHY Do we need APPRESCI?

Improving HEALTH


Acute pancreatitis (AP) is a major unmet medical need. For every 100,000 population, AP affects about 50 people per year. This equates to about 30,000 people affected by AP in the UK every year. The number of people affected by AP is increasing throughout the world.

At the moment, we don't have any specific treatments for AP. Therefore any incremental benefit that can be achieved in AP will have a massive impact on healthcare globally.

Our vision is to personalise the healthcare for individuals with AP, through the development of a robust precision medicine framework.

Source: BMJ Open 2016.


The current general understanding of AP is of a single disease with a range of outcomes, usually categorised into mild, moderate and severe.We believe that AP is actually a collection of different subtypes, that, when combined with person-specific and episode-specific factors, has an illness response that is unique to any given individual.

Opportunities for immediate translation of the APPreSci findings include discovery of new strategies to make medicines, directing location of care (especially home-from- hospital vs. critical care for patients), innovation of near-patient testing technology, and guiding bespoke follow-up. These are all factors that will contribute to a much improved overall experience for patients with AP.


The financial cost of acute hospital care for AP is staggering - an estimated £200 million annually in the UK and $3.7 billion in the US.

However, the human cost is greater - the fatality rate for AP-MODS is 21% during the acute episode and there is a lasting negative effect of AP-MODS (compared to AP without MODS) on all-cause mortality. Therefore, it is clear that AP represents a significant unmet medical need which APPreSci can fill.

Source: BMJ Open 2016.

You can listen to the stories of patients who have had AP on our 'Patient Partners' page, and read more about our goals on our 'Scientific Goals' page.